A silver-containing pharmaceutical product : study of the absorption of silver in rats by (105 + 106)Ag radiotracer and assessment of the potential health impactFunded under: JRC-ENVPROT 4C
The (105 + 106)Ag radioisotopes, produced at the cyclotron by proton bombardment of metallic palladium, were used to label a pharmaceutical product (AGIPIU) which is used as a topical disinfectant and cicatrizant for the treatment of skin lesions. When applied to the skin of rats, it leads to the presence of traces of Ag in blood, liver, kidney, testicles, spleen, femur and heart, ranging from below 0.0001 to 0.004% of the dose. However, the amount of Ag was 10 times greater in the stomach, suggesting a possible ingestion of traces of the product during the experiments. Thus, the amounts of Ag found in the tissues analysed and ascribed to absorption from the site of application on the abrasions may have been overestimated. In any case, the trace amounts of silver incorporated in the tissues correspond to a maximum estimated retention of 0.01% of the dose. An assessment of the potential health impact of the Ag - disinfecting agent was carried out on two main assumptions: (i) the liver is a target of silver toxicity and the hepatic silver concentration could be an index of the only well-established toxic effect induced by exposure to Ag salts (argyria) (ii) the health impact on the patients can be assessed by extrapolating the results from animal experimentation. The assessment study strongly suggests that the silver absorbed during the treatment of the lesions would not reach levels which would induce toxic effects.
Bibliographic Reference: EUR 12058 EN (1989) MF, 17 pp., ECU 4, blow-up copy ECU 5
Record Number: 198911165 / Last updated on: 1994-12-01
Original language: en
Available languages: en